Evogene Ltd., a computational chemistry company, has reached a cooperation agreement with Pure Capital Group to resolve disputes following contested voting results and a proposed tender offer. The deal includes replacing four board members with Pure Capital nominees and a 60-day standstill on share issuance, stabilizing the company to focus on its AI-driven drug and ag-chemical molecule discovery technology, ChemPass AI™. This agreement avoids costly legal battles and aims to support Evogene's growth and innovation in pharmaceuticals and agriculture.
Evogene's recent cooperation agreement with Pure Capital Group provides context for readers. For those following the health sector, here is Pluang's market snapshot as of Oct 07, 2026 01:01 WIB: out of 100 priced US health stocks, 28 advanced while 71 declined. Notable movers include GeneDx Holdings Corp (WGS) at USD 71.08 with a -6.80% change and 100% buy order activity, Moderna, Inc. (MRNA) at USD 190.01 with a -6.50% change and nearly balanced buy/sell activity, and Illumina, Inc. (ILMN) at USD 277.31 with a -5.58% change and 78% buy order activity.
Constellation Brands reported earnings per share of $3.74, surpassing analyst estimates of $3.55, and revenue of $2.63 billion, exceeding the $2.54 billion forecast. The company saw a 5% increase in beer sales and a 17% rise in wine and spirits sales...
Tilray Brands will announce its fiscal Q1 2027 earnings on October 8, with analysts forecasting a loss of $0.16-$0.19 per share on revenues around $265-$268 million, marking about 26% growth from last year. Investors will focus on cannabis and bevera...
On October 6, 2026, five notable stocks surged between 20.9% and 52.7%, driven by various positive developments. Apimeds Pharmaceuticals rose 52.7% after its subsidiary signed a blockchain contract, while Option Care Health gained 32.7% following a $...
On October 6, five notable stocks saw significant declines, with losses ranging from 17.5% to 50.1%. ArriVent BioPharma's shares plunged 46.9% after its lung cancer treatment failed to meet the primary endpoint in a Phase 3 trial. Armada Acquisition ...
Evercore ISI raised its price target for Marvell Technology to $433 from $275, maintaining an Outperform rating. This follows Marvell's optimistic revenue projections, expecting $20 billion by fiscal 2028 and $70-$90 billion by fiscal 2031, driven by...
